Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.
Non-Hodgkins Lymphoma|B-cell Lymphoma|Waldenstrom's Macroglobulinemia|Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL)|Primary Central Nervous System Lymphoma
DRUG: Ublituximab
Number of Participants with Adverse Events as a Measure of Safety and Tolerability, Safety for all study patients will be evaluated by a Data Safety Monitoring Board to determine if feasible to continue with dose escalation, Subjects will be followed for 4 weeks|Maximum Tolerated Dose acceptable for participants, The Maximum Tolerated Dose will be determined by a Data Safety Monitoring Board, Subjects will be followed for 4 weeks
Efficacy, Efficacy will include overall response rate, duration of response and progression-free survival, Participants will be evaluated approximately every 8 - 12 weeks
Pharmacokinetic profile including Peak Plasma Concentration (Cmax)" or "Area Pharmacokinetic profile including Peak Plasma Concentration (Cmax) and Area under the plasma concentration versus time curve (AUC), Up to 6 months
The purpose of this study is to determine whether ublituximab is safe and effective in patients with relapsed or refractory B-cell lymphoma who were previously treated with rituximab.